Recap: Eton Pharmaceuticals Q4 Earnings
Portfolio Pulse from Benzinga Insights
Eton Pharmaceuticals (NASDAQ:ETON) reported Q4 earnings with an EPS of $-0.09, missing estimates by -125.0% and a revenue decrease of $1.19 million from the previous year. This follows a pattern of past earnings where a beat or miss on EPS estimates led to significant share price movements.
March 14, 2024 | 8:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eton Pharmaceuticals reported a significant miss in Q4 earnings with an EPS of $-0.09, underperforming estimates by -125.0%, and a year-over-year revenue decrease.
Given ETON's history of share price movements following earnings reports, the significant miss in both EPS and revenue is likely to negatively impact the stock price in the short term. The pattern observed from past earnings suggests that misses lead to share price declines.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100